Form D · Biotechnology
Evozym Biologics, Inc.
Lewes, DE · CIK 0001536704
Offering snapshot reported Dec 9, 2011 · SEC filing
- Reported sold
- $600K Offering amount: $600K
- Investors reported
- 10 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 30, 2011 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 9, 2011 | Initial | $600,000 | No comparison | 10 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-169831
Source: Form D, filed Dec 9, 2011. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Gregg Abella | Director |
| John Connor | Director |
| Joseph J Grzymski | Director, Executive, Promoter |
| Adam G Marsh | Director, Executive, Promoter |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
19812 Shirling Lane
Lewes, DE, 19958
Lewes, DE, 19958